We are monitoring the impact of COVID-19 on North America Immunotherapy Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1093
Share on
Share on

North America Immunotherapy Drugs Market Research Report – Segmented By Drug Type, Application & Country (United States, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, Growth & Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1093
Pages: 145

North America Immunotherapy Drugs Market Size (2021 to 2026)

The size of the Immunotherapy Drugs Market in North America was valued at USD 47.55 billion in 2021 and is calculated to reach USD 76.93 billion by 2026, growing at a CAGR of 10.1% during the forecast period.

With the rising incidences of cancer cases and autoimmune diseases, there has been an increasing demand for immunotherapy drugs and is likely to have a positive outlook for its market in the forecast period. Immunotherapy is a type of treatment for cancer which enhances the immune system to fight against cancer. Immunotherapies either stimulate the activity done by a particular component of the immune system or counteract the immune system produced by the cancer cells suppressing the immune responses.

With the evolution of innovation and technology, increasing prevalence of cancer and autoimmune diseases, immunotherapy drugs are expected to gain significance in the future. Other driving factors for the immunotherapy drugs include rising incidences of diseases, higher efficiency than the standard drugs, acceleration in the development and review of new drugs.

However, the market is dampened by the high costs involving immunotherapy drugs and limited access to the lower and middle-income groups.

This research report on the North America Immunotherapy Drugs Market has been segmented and sub-segmented into the following categories

  • By Drug Type: Monoclonal antibodies, Interferons, Interleukins, Vaccines, checkpoint inhibitors.
  • By Application: Blood Cancer, Cervical Cancer, Breast Cancer, Glioblastoma, Lung Cancer, Gastric Cancer, Prostate Cancer, Melanoma.
  • By Country: the United States, Canada & Rest of North America.

Based on the region, North America is currently the leading market with most of the share and is likely to sustain in the review period. It is attributed to the higher incidences of cancer and infectious diseases coupled with high affordability and well-structured reimbursement plans. North America was dominated by the global immunotherapy drugs market in 2019 and is expected to dominate the market due to the growing occurrence rate of cancer cases and autoimmune diseases. Growing demand for immunotherapy drugs has a positive outlook on the market. Key players are coming up with initiatives in manufacturing medicines for cancer and increasing expenditure on healthcare by the government.

The U.S. immunotherapy drugs market is dominating the North American market. In the U.S., breast cancer, lung, bronchus, and others are the most commonly occurring cancers. It is estimated that 1,685 210 new cancer cases were diagnosed, and around 595,690 deaths occurred due to cancer, according to the National Cancer Institute in 2016.    

The Canadian immunotherapy drugs market is next to the U.S. in accounting for the highest share in the North American market due to infectious diseases incorporated with high affordability and well-structured reimbursement plans. Growth in the biotechnology and pharmaceutical industries, rising elderly people population, and increasing healthcare expenditure will accelerate the immunotherapy drugs market growth of this region.

Promising Companies dominating the North America Immunotherapy Drugs Market Profiled in the Report are Roche, Merck, Eli Lilly, Novartis, AstraZeneca, GlaxoSmithKline PLC, Amgen, Celgene, Bristol Myers Squibb, and Seattle Genetics.

1. Introduction                 

                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods           

                1.4 General Study Assumptions

2. Research Methodology                           

                2.1 Introduction              

                2.2 Research Phases      

                                2.2.1 Secondary Research

                                2.2.2 Primary Research

                                2.2.3 Econometric Modelling

                                2.2.4 Expert Validation

                2.3 Analysis Design         

                2.4 Study Timeline          

3. Overview                      

                3.1 Executive Summary

                3.2 Key Inferences         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                      

                4.1 Market Drivers          

                4.2 Market Restraints    

                4.3 Key Challenges         

                4.4 Current Opportunities in the Market

5. Market Segmentation                              

                5.1 By Drug Type             

                                5.1.1 Monoclonal Antibodies

                                5.1.2 Interferons

                                5.1.3 Interleukins

                                5.1.4 Vaccines

                                5.1.5 Checkpoint Inhibitors

                5.2 By Application           

                                5.2.1 Blood Cancer

                                5.2.2 Cervical Cancer

                                5.2.3 Breast Cancer

                                5.2.4 Glioblastoma

                                5.2.5 Lung Cancer

                                5.2.6 Gastric Cancer

                                5.2.7 Prostate Cancer

                                5.2.8 Melanoma

6. Geographical Analysis                              

                6.1 Introduction              

                6.2 United States            

                6.3 Canada         

7. Pipeline Product Analysis                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                     

                7.4 Clinical Trials              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.

8. Strategic Analysis                       

                8.1 PESTLE analysis         

                                8.1.1 Political

                                8.1.2 Economic

                                8.1.3 Social

                                8.1.4 Technological

                                8.1.5 Legal

                                8.1.6 Environmental

                8.2 Porter’s Five analysis              

                                8.2.1 Bargaining Power of Suppliers

                                8.2.2 Bargaining Power of Consumers

                                8.2.3 Threat of New Entrants

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry

9. Market Leaders' Analysis                        

                9.1 Eli Lilly           

                                9.1.1 Overview

                                9.1.2 Product Analysis

                                9.1.3 Financial analysis

                                9.1.4 Recent Developments

                                9.1.5 SWOT analysis

                                9.1.6 Analyst View

                9.2 Merck           

                9.3 Roche           

                9.4 Amgen         

                9.5 Novartis       

                9.6 Celgene       

                9.7 AstraZeneca

                9.8 Bristol Myers Squibb              

                9.9 GlaxoSmithKline PLC              

                9.10 Seattle Genetics    

10. Competitive Landscape                         

                10.1 Market share analysis          

                10.2 Merger and Acquisition Analysis     

                10.3 Agreements, collaborations and Joint Ventures       

                10.4 New Product Launches       

11. Market Outlook and Investment Opportunities                          

Appendix                           

                a) List of Tables

                b) List of Figures              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Immunotherapy Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  2. North America Immunotherapy Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  3. North America Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  4. North America Interferons Market, By Region, From 2021 to 2026 (USD Billion)
  5. North America Interleukins Market, By Region, From 2021 to 2026 (USD Billion)
  6. North America Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  7. North America Checkpoint Inhibitors Market, By Region, From 2021 to 2026 (USD Billion)
  8. North America Immunotherapy Drugs Market, By Application, From 2021 to 2026 (USD Billion)
  9. North America Blood Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  10. North America Cervical Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  11. North America Breast Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  12. North America Glioblastoma Market, By Region, From 2021 to 2026 (USD Billion)
  13. North America Lung Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  14. North America Gastric Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  15. North America Prostate Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  16. North America Melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  17. United States Immunotherapy Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  18. United States Immunotherapy Drugs Market, By Application, From 2021 to 2026 (USD Billion)
  19. Canada Immunotherapy Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  20. Canada Immunotherapy Drugs Market, By Application, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample